SynthesisFrontiers in pharmacology2024

Cabozantinib in combination with immune checkpoint inhibitors for renal cell carcinoma: a systematic review and meta-analysis.

Jingyang Su et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.